Proposal for a new tool to evaluate drug interaction cases

Annals of Pharmacotherapy

Volumn 41, Issue 4, 2007, Pages 674-680

  Horn, John R ^a,b,c   Hansten, Philip D ^c   Chan, Lingtak Neander ^c  

^a School of Pharmacy   (United States)

^b UNIVERSITY OF WASHINGTON MEDICAL CENTER   (United States)

^c UNIVERSITY OF WASHINGTON   (United States)

Author keywords

Causation; Drug interactions; Probabity

Indexed keywords

ANTIBIOTIC AGENT; AZITHROMYCIN; CYCLOSPORIN; CYTOCHROME P450 3A4; GLYCOPROTEIN P; VITAMIN K GROUP; WARFARIN;

ARTICLE; DIAGNOSTIC ACCURACY; DRUG CROSS REACTIVITY; DRUG INTERACTION PROBABILITY SCALE; DRUG MECHANISM; EVALUATION; HUMAN; NOMOGRAM; OUTCOMES RESEARCH; PRIORITY JOURNAL; PROBABILITY; RATING SCALE;

CAUSALITY; DRUG ADMINISTRATION SCHEDULE; DRUG INTERACTIONS; HUMANS; PHARMACOKINETICS; PROBABILITY; QUESTIONNAIRES; TIME FACTORS;

EID: 34247231457     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.1H423     Document Type: Article

References (15)

1. Naranjo CA, Busto U, Sellers EM, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther 1981;30:239-45.
2. Jones JK. Adverse drug reactions in the community health setting: approaches to recognizing, counseling, and reporting. Fam Commun Health 1982;5:58-67.
3. Kramer MS, Leventhal JM, Hutchinson TA, Feinstein AR. An algorithm for the operational assessment of adverse drug reactions. I. Background, description, and instructions for use. JAMA 1979;242:623-32.
4. Mashford ML. The Australian method of drug-event assessment. Drug Inf J 1984;18:271-3.
5. Karch FE, Lasagna L. Toward the operational identification of adverse drug reactions. Clin Pharmacol Ther 1977;21:247-54.
6. Koh Y, Li SC. A new algorithm to identify the causality of adverse drug reactions. Drug Saf 2005;28:1159-61.
7. Michel DJ, Knodel LC. Comparison of three algorithms used to evaluate adverse drug reactions. Am J Hosp Pharm 1986;43:1709-14.
8. Berry LL, Segal R, Sherrin TP, Fudge KA. Sensitivity and specificity of three methods of detecting adverse drug reactions. Am J Hosp Pharm 1988;45:1534-9.
9. Kane-Gill SL, Kirisci L, Pathak DS. Are the Naranjo criteria reliable and valid for determination of adverse drug reactions in the intensive care unit? Ann Pharmacother 2005;39:1823-7. Epub 4 Oct 2005. DOI 10.1345/aph.1G177
10. Hansten PD, Horn JR. The top 100 drug interactions: a guide to patient management. 2006 ed. Freeland, WA: H&H Publications, LLP, 2006: 230-1.
11. Page RL, Ruscin JM, Fish D, LaPointe M. Possible interaction between intravenous azithromycin and oral cyclosporine. Pharmacotherapy 2001; 21:1436-43.
12. Ljutic D, Rumboldt Z. Possible interaction between azithromycin and cyclosporin: a case report. Nephron 1995;70:130.
13. Gomez E, Sanchez JE, Aguado S, Alvarez-Grande J. Interaction between azithromycin and cyclosporin? Nephron 1966;73:724.
14. Strachan D, Burton I, Pearson GJ. Is oral azithromycin effective for the treatment of cyclosporine-induced gingival hyperplasia in cardiac transplant recipients? J Clin Pharm Ther 2003;28:329-38.
15. Bachmann K, Jauregui L, Chandra R, Thakker K. Influence of a 3-day regimen of azithromycin on the disposition kinetics of cyclosporine A in stable renal transplant patients. Pharmacol Res 2003;47:549-54.